Fate of lymphocytes after withdrawal of tofacitinib treatment

Elisa Piscianz, Erica Valencic, Eva Cuzzoni, Sara De Iudicibus, Elisa De Lorenzo, Giuliana Decorti, Alberto Tommasini

Research output: Contribution to journalArticle

Abstract

Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. However, few studies have investigated the effects of Tofa on lymphocyte activation in vitro. Our aim was to study the action of Tofa on different lymphocyte subsets after in vitro stimulation and to track the behaviour of treated cells after interruption of the treatment. Peripheral blood lymphocytes were stimulated in vitro with mitogen and treated with two concentrations of Tofa. After a first period in culture, cells were washed and further incubated for an additional time. Lymphocyte subsets, activation phenotype and proliferation were assessed at the different time frames. As expected, Tofa was able to reduce the activation and proliferation of lymphocytes in the first four days of treatment. In addition the drug led to a relative decrease of Natural Killer, B cells and CD8 T cells compared to CD4 T cells. However, treated cells were still viable after the first period in culture and begun to proliferate, strikingly, in a dose dependent manner when the drug was removed from the environment by replacing the culture medium. This novel data does not necessarily predict a similar behaviour in vivo, but can warn about the clinical use of this drug when a discontinuation of treatment with Tofa is considered for any reason.

Original languageEnglish
Article numbere85463
JournalPLoS One
Volume9
Issue number1
DOIs
Publication statusPublished - Jan 9 2014

Fingerprint

Lymphocytes
lymphocyte proliferation
lymphocytes
T-lymphocytes
T-cells
drugs
Lymphocyte Activation
Chemical activation
non-specific protein-tyrosine kinase
cells
graft rejection
Lymphocyte Subsets
Cells
T-Lymphocytes
autoimmune diseases
Janus Kinase 3
B-lymphocytes
Pharmaceutical Preparations
cell culture
culture media

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Agricultural and Biological Sciences(all)

Cite this

Piscianz, E., Valencic, E., Cuzzoni, E., De Iudicibus, S., De Lorenzo, E., Decorti, G., & Tommasini, A. (2014). Fate of lymphocytes after withdrawal of tofacitinib treatment. PLoS One, 9(1), [e85463]. https://doi.org/10.1371/journal.pone.0085463

Fate of lymphocytes after withdrawal of tofacitinib treatment. / Piscianz, Elisa; Valencic, Erica; Cuzzoni, Eva; De Iudicibus, Sara; De Lorenzo, Elisa; Decorti, Giuliana; Tommasini, Alberto.

In: PLoS One, Vol. 9, No. 1, e85463, 09.01.2014.

Research output: Contribution to journalArticle

Piscianz, E, Valencic, E, Cuzzoni, E, De Iudicibus, S, De Lorenzo, E, Decorti, G & Tommasini, A 2014, 'Fate of lymphocytes after withdrawal of tofacitinib treatment', PLoS One, vol. 9, no. 1, e85463. https://doi.org/10.1371/journal.pone.0085463
Piscianz E, Valencic E, Cuzzoni E, De Iudicibus S, De Lorenzo E, Decorti G et al. Fate of lymphocytes after withdrawal of tofacitinib treatment. PLoS One. 2014 Jan 9;9(1). e85463. https://doi.org/10.1371/journal.pone.0085463
Piscianz, Elisa ; Valencic, Erica ; Cuzzoni, Eva ; De Iudicibus, Sara ; De Lorenzo, Elisa ; Decorti, Giuliana ; Tommasini, Alberto. / Fate of lymphocytes after withdrawal of tofacitinib treatment. In: PLoS One. 2014 ; Vol. 9, No. 1.
@article{33dbe67c4e914cafb5761d4e803df755,
title = "Fate of lymphocytes after withdrawal of tofacitinib treatment",
abstract = "Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. However, few studies have investigated the effects of Tofa on lymphocyte activation in vitro. Our aim was to study the action of Tofa on different lymphocyte subsets after in vitro stimulation and to track the behaviour of treated cells after interruption of the treatment. Peripheral blood lymphocytes were stimulated in vitro with mitogen and treated with two concentrations of Tofa. After a first period in culture, cells were washed and further incubated for an additional time. Lymphocyte subsets, activation phenotype and proliferation were assessed at the different time frames. As expected, Tofa was able to reduce the activation and proliferation of lymphocytes in the first four days of treatment. In addition the drug led to a relative decrease of Natural Killer, B cells and CD8 T cells compared to CD4 T cells. However, treated cells were still viable after the first period in culture and begun to proliferate, strikingly, in a dose dependent manner when the drug was removed from the environment by replacing the culture medium. This novel data does not necessarily predict a similar behaviour in vivo, but can warn about the clinical use of this drug when a discontinuation of treatment with Tofa is considered for any reason.",
author = "Elisa Piscianz and Erica Valencic and Eva Cuzzoni and {De Iudicibus}, Sara and {De Lorenzo}, Elisa and Giuliana Decorti and Alberto Tommasini",
year = "2014",
month = "1",
day = "9",
doi = "10.1371/journal.pone.0085463",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Fate of lymphocytes after withdrawal of tofacitinib treatment

AU - Piscianz, Elisa

AU - Valencic, Erica

AU - Cuzzoni, Eva

AU - De Iudicibus, Sara

AU - De Lorenzo, Elisa

AU - Decorti, Giuliana

AU - Tommasini, Alberto

PY - 2014/1/9

Y1 - 2014/1/9

N2 - Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. However, few studies have investigated the effects of Tofa on lymphocyte activation in vitro. Our aim was to study the action of Tofa on different lymphocyte subsets after in vitro stimulation and to track the behaviour of treated cells after interruption of the treatment. Peripheral blood lymphocytes were stimulated in vitro with mitogen and treated with two concentrations of Tofa. After a first period in culture, cells were washed and further incubated for an additional time. Lymphocyte subsets, activation phenotype and proliferation were assessed at the different time frames. As expected, Tofa was able to reduce the activation and proliferation of lymphocytes in the first four days of treatment. In addition the drug led to a relative decrease of Natural Killer, B cells and CD8 T cells compared to CD4 T cells. However, treated cells were still viable after the first period in culture and begun to proliferate, strikingly, in a dose dependent manner when the drug was removed from the environment by replacing the culture medium. This novel data does not necessarily predict a similar behaviour in vivo, but can warn about the clinical use of this drug when a discontinuation of treatment with Tofa is considered for any reason.

AB - Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. However, few studies have investigated the effects of Tofa on lymphocyte activation in vitro. Our aim was to study the action of Tofa on different lymphocyte subsets after in vitro stimulation and to track the behaviour of treated cells after interruption of the treatment. Peripheral blood lymphocytes were stimulated in vitro with mitogen and treated with two concentrations of Tofa. After a first period in culture, cells were washed and further incubated for an additional time. Lymphocyte subsets, activation phenotype and proliferation were assessed at the different time frames. As expected, Tofa was able to reduce the activation and proliferation of lymphocytes in the first four days of treatment. In addition the drug led to a relative decrease of Natural Killer, B cells and CD8 T cells compared to CD4 T cells. However, treated cells were still viable after the first period in culture and begun to proliferate, strikingly, in a dose dependent manner when the drug was removed from the environment by replacing the culture medium. This novel data does not necessarily predict a similar behaviour in vivo, but can warn about the clinical use of this drug when a discontinuation of treatment with Tofa is considered for any reason.

UR - http://www.scopus.com/inward/record.url?scp=84897384127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897384127&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0085463

DO - 10.1371/journal.pone.0085463

M3 - Article

C2 - 24416411

AN - SCOPUS:84897384127

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e85463

ER -